Literature DB >> 8425762

K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos.

K Husgafvel-Pursiainen1, P Hackman, M Ridanpää, S Anttila, A Karjalainen, T Partanen, O Taikina-Aho, L Heikkilä, H Vainio.   

Abstract

We investigated point mutational activation of the ras genes (K-ras codons 12, 13 and 61; N-ras codons 12, 13 and 61; H-ras codons 12 and 61) in primary, resected lung cancer by dot blotting and oligonucleotide hybridization. K-ras mutations were found in 14 (29%) of the 48 lung tumour specimens examined, but no N-ras or H-ras mutations were found. The highest frequency of K-ras mutation was observed in adenocarcinoma: 12 of the 21 samples studied (57%) had a mutation, which is one of the highest frequencies reported for lung adenocarcinoma. The commonest type of mutation in these lung tumour samples consisted of transversions: we observed 11, of which 8 (57% of all mutations) were G to T transversions. Most of the 48 patients studied had a history of heavy smoking, either with or without evidence of occupational exposure to asbestos. Statistical analysis revealed--in addition to the highly significant association between the adenocarcinoma type of lung cancer and K-ras mutation--a clear association of K-ras mutations with heavy life-time smoking (> or = 50 pack-years of cigarette smoking; odds ratio (OR) 4.9, 90% CI 1.2-19.5, multivariate analysis). In addition, occupational asbestos exposure showed an elevated, but non-significant, OR of 2.2 (90% CI 0.6-8.7) with the presence of K-ras mutation. We conclude that the occurrence of K-ras mutations in adenocarcinoma of the lung is frequent, and that such mutations are associated with heavy life-time exposure to tobacco smoke, possibly in combination with occupational exposure to asbestos fibres.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425762     DOI: 10.1002/ijc.2910530213

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

Review 1.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

2.  Structural destabilization of DNA duplexes containing single-base lesions investigated by nanopore measurements.

Authors:  Qian Jin; Aaron M Fleming; Yun Ding; Cynthia J Burrows; Henry S White
Journal:  Biochemistry       Date:  2013-10-31       Impact factor: 3.162

3.  EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer.

Authors:  David E Gerber
Journal:  Drug Dev Res       Date:  2008-12-09       Impact factor: 4.360

4.  Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.

Authors:  Satu Mäki-Nevala; Virinder Kaur Sarhadi; Aija Knuuttila; Ilari Scheinin; Pekka Ellonen; Sonja Lagström; Mikko Rönty; Eeva Kettunen; Kirsti Husgafvel-Pursiainen; Henrik Wolff; Sakari Knuutila
Journal:  Lung       Date:  2016-02       Impact factor: 2.584

Review 5.  Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos.

Authors:  Brooke T Mossman; Morton Lippmann; Thomas W Hesterberg; Karl T Kelsey; Aaron Barchowsky; James C Bonner
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

6.  Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer.

Authors:  Colleen R Maier; M Christine Hollander; Evthokia A Hobbs; Irem Dogan; R Ilona Linnoila; Phillip A Dennis
Journal:  Cancer Prev Res (Phila)       Date:  2011-10-25

7.  Ras in cancer and developmental diseases.

Authors:  Alberto Fernández-Medarde; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

8.  K-ras mutations in sinonasal cancers in relation to wood dust exposure.

Authors:  Jette Bornholdt; Johnni Hansen; Torben Steiniche; Michael Dictor; Annemarie Antonsen; Henrik Wolff; Vivi Schlünssen; Reetta Holmila; Danièle Luce; Ulla Vogel; Kirsti Husgafvel-Pursiainen; Håkan Wallin
Journal:  BMC Cancer       Date:  2008-02-20       Impact factor: 4.430

9.  Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?

Authors:  Seung Tae Kim; Jae Sook Sung; Uk Hyun Jo; Kyong Hwa Park; Sang Won Shin; Yeul Hong Kim
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

Review 10.  Cancer epidemiology: study designs and data analysis.

Authors:  N Malats; G Castaño-Vinyals
Journal:  Clin Transl Oncol       Date:  2007-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.